Phase 1Completed
TMC435-TiDP16-C108 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Digoxin and Between TMC435 and Rosuvastatin
A Phase I, 2-panel, Open-label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and Transporter Substrates, Digoxin and Rosuvastatin
- Sponsor
- Tibotec Pharmaceuticals, Ireland (Industry)
- Enrollment
- 33 enrolled
- Conditions
- Hepatitis C Virus
- Interventions
- Rosuvastatin; Rosuvastatin; TMC435; Digoxin; Digoxin
- Ages
- adults
- Registry
- NCT01288742
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to investigate the effect of steady-state concentrations of TMC435 on the single-dose pharmacokinetics of digoxin or rosuvastatin , and the effect of a single dose of digoxin or rosuvastatin on the steady-state pharmacokinetics of TMC435. Steady state is a term that means that the drug has been given long enough so that the plasma concentrations will remain the same with each subsequent dose. TMC435 is being investigated for the treatment of chronic hepatitis C virus (HCV) infection. Pharmacokinetics (PK) means how the drug is absorbed into the bloodstream, distributed in the body, and eliminated from the body.
Primary outcomes
- Change in absorption of TMC435 following co-administration with Digoxin (Panel 1).
- Change in absorption of Digoxin following co-administration with TMC435 (Panel 1).
- Change in absorption of TMC435 following co-administration with rosuvastatin (Panel 2).
- Change in absorption of rosuvastatin following co-administration with TMC435 (Panel 2).
History
Last registry update
Primary completion
Registered
Started